Conatus Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2005-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.conatuspharma.com
Clinical Trials
22
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (21 trials with phase data)• Click on a phase to view related trials
Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo
- Conditions
- Liver DiseasesDecompensated Non-Alcoholic Steatohepatitis CirrhosisNASH FibrosisOrthotopic Liver TransplantationLiver FibrosisLiver Cirrhosis
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Conatus Pharmaceuticals Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03479125
- Locations
- 🇺🇸
Inland Empire Liver Foundation, Rialto, California, United States
🇺🇸Options Health Research, LLC, Tulsa, Oklahoma, United States
🇺🇸Gastro One, Germantown, Tennessee, United States
Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis
- Conditions
- Decompensated Cirrhosis
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Conatus Pharmaceuticals Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT03205345
- Locations
- 🇺🇸
The Institute for Liver Health, Chandler, Arizona, United States
🇺🇸St. Joseph's Hospital & Medical Center, Phoenix, Arizona, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
- Conditions
- Non-alcoholic SteatohepatitisLiver DiseasesFibrosis
- Interventions
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- Conatus Pharmaceuticals Inc.
- Target Recruit Count
- 318
- Registration Number
- NCT02686762
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Arizona Clinical and Translational Sciences Research Center, Tucson, Arizona, United States
🇺🇸Preferred Research Partners, Inc., Little Rock, Arkansas, United States
A Study of IDN-6556 in Subjects With Liver Cirrhosis
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- Conatus Pharmaceuticals Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT02230670
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Scripps Clinic, La Jolla, California, United States
🇺🇸Loma Linda University Medical Center, Loma Linda, California, United States
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
- Conditions
- Hepatic CirrhosisPortal HypertensionLiver Cirrhosis
- Interventions
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2016-12-21
- Lead Sponsor
- Conatus Pharmaceuticals Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT02230683
- Locations
- 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States
🇺🇸Johns Hopkins Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸University of Miami, Miami, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- Next